David Starr et al. v. VSL Pharmaceuticals, Inc. et al.

CourtDistrict Court, D. Maryland
DecidedJuly 9, 2026
Docket8:19-cv-02173
StatusUnknown

This text of David Starr et al. v. VSL Pharmaceuticals, Inc. et al. (David Starr et al. v. VSL Pharmaceuticals, Inc. et al.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
David Starr et al. v. VSL Pharmaceuticals, Inc. et al., (D. Md. 2026).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

) DAVID STARR et al., ) ) Plaintiffs, ) ) Civil Action No. 19-cv-02173-LKG v. ) ) Dated: July 8, 2026 VSL PHARMACEUTICALS, INC. et al., ) ) Defendants. ) )

MEMORANDUM OPINION AND ORDER ON THE PLAINTIFFS’ MOTION FOR PRELIMINARY APPROVAL OF CLASS ACTION SETTLEMENT

I. INTRODUCTION The Plaintiffs in this class action litigation have filed an unopposed motion for preliminary approval of class action settlement, to resolve their claims against the Defendants, VSL Pharmaceuticals, Inc. (“VSL”), Leadiant Biosciences, Inc., f/k/a Sigma-Tau Pharmaceuticals, Inc. (“Leadiant”), and Alfasigma USA, Inc. (“Alfasigma”). See ECF No. 376. The Court held a hearing on this motion on July 7, 2026. ECF No. 378. For the reasons that follow, and those stated during the July 7, 2026, hearing, the Court: (1) GRANTS the Plaintiffs’ motion for preliminary approval of class action settlement (ECF No. 376); (2) CONDITIONALLY CERTIFIES the Settlement Class; (3) APPROVES Plaintiffs David Starr, Bernadette Mavrikos, Edmund Quiambao, James Tettenhorst, Jeremy Hansen, Krista Karo, Arlene Reed- Cossairt, Peter Stavros and Heather Farkas to represent the Settlement Class; (4) APPOINTS Jeremy W. Schulman, Esq., and Jeffrey S. Gavenman, Esq., of Hughes Hubbard & Reed LLP, and Edward F. Haber, Esq., Michelle H. Blauner, Esq., Ian J. McLoughlin, Esq., and Patrick J. Vallely, Esq., of Shapiro Haber & Urmy LLP as the Settlement Class Counsel; (5) APPOINTS Angeion Group LLC as the Settlement Administrator; and (6) PRELIMINARILY APPROVES the Settlement Agreement. II. FACTUAL BACKGROUND AND PROCEDURAL HISTORY1 A. Factual Background Case Background This class action matter concerns the marketing and sale of VSL#3, a high-potency probiotic medical food used in the dietary management of gastrointestinal conditions, such as ulcerative colitis, irritable bowel syndrome and pouchitis. ECF No. 93 at ¶¶ 1, 42–45. The Plaintiffs allege that, from in or about 2002, until mid-2016, VSL#3 contained a proprietary blend of bacterial strains developed by Professor Claudio De Simone (the “De Simone Formulation”). Id. at ¶¶ 2, 47–54. The Plaintiffs also allege that the Defendants lost the right to sell the De Simone Formulation and began selling a different and inferior formulation (the “Fraudulent Formulation”) under the “VSL#3,” while continuing to invoke the clinical history and scientific support associated with the original De Simone Formulation and omitting to disclose that the formulation had changed. Id. at ¶¶ 4–8, 65–67. And so, the Plaintiffs assert claims against the Defendants for: (1) violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1962(c) and (d); (2) breach of express warranty in violation of the Uniform Commercial Code (“UCC”); (3) unjust enrichment; and (4) violations of the consumer protection statutes of several states. Id. at ¶¶ 185–299; ECF No. 376-1 at 3. The Settlement Agreement

The parties have entered into a settlement agreement and release (the “Settlement Agreement”) to resolve the Plaintiffs’ claims. ECF No. 376-3 at 5–36 (Exhibit A). The key provisions of the Settlement Agreement are summarized below. First, the parties propose defining and certifying a “Settlement Class” in this case as follows: [A]ll persons who purchased a VSL#3 Class Product in the United States beginning June 1, 2016, and ending June 19, 2019. The following individuals are excluded from the Settlement Class: officers and directors of Defendants Alfasigma, Leadiant, and VSL, and their parents, subsidiaries, affiliates, and any entity in which

1 The facts recited herein are taken from the second amended complaint, the Plaintiffs’ consent motion for preliminary approval of the settlement, and the memorandum of law and exhibits in support thereof. ECF Nos. 93, 376, 376-1, 376-2, 376-3 and 376-4. Unless otherwise stated, the facts recited herein are undisputed. they have a controlling interest. Also excluded from the Class are any persons or entities that purchased VSL#3 Class Products exclusively for the purpose of reselling the VSL#3 Class Product to a consumer. Finally, also excluded from the Class are all judges assigned to hear any aspect of the Litigation, as well as their staff and immediate family; and Settlement Class Counsel, their staff members, and their immediate family. Id. at 11. The proposed Settlement Class is substantially similar to the “Nationwide Class” that the Court previously certified in this case, except that the proposed Settlement Class does not include the officers and directors of the Defendants and their affiliates, persons or entities that purchased VSL#3 exclusively for resale, Court personnel, and Settlement Class Counsel and their respective staff and families. Id. at 12 (Settlement Agreement, § 1.49); see ECF No. 376-1 at 7. Second, Sections 1.56 and 3.2 of the Settlement Agreement address the settlement consideration and provide, among other things, that the Defendants will pay $20 million for the benefit of the Settlement Class. ECF No. 376-1 at 7–8; ECF No. 376-3 at 12 (Settlement Agreement, § 1.56) and 15 (Settlement Agreement, § 3.2). Pursuant to the Settlement Agreement, these Settlement Funds will be used to create a common fund to pay: (1) valid claims made by the Settlement Class Members; (2) the attorneys’ fees and expenses of Settlement Class Counsel; (3) the costs of providing notice and administering the Settlement; and (4) any service awards to the Plaintiffs as approved by the Court. ECF No. 376-1 at 7–8. Third, Sections 2.4, 3.2 and 3.3 of the Settlement Agreement address the calculation and disbursement of the Settlement Funds and provide that the “Net Settlement Fund,” which is the amount remaining of the Settlement Funds after the award of Class Counsel’s fees and expenses, administrative costs and service awards, will be distributed to members of the Settlement Class according to a plan of distribution. Id.; ECF No. 376-3 at 14–15 (Settlement Agreement, § 2.4), 16—20 (Settlement Agreement, § 3.2), 20–21 (Settlement Agreement, § 3.3). In this regard, the Settlement Agreement provides that a Settlement Class Member must submit a Claim Form, which will either be mailed to the Settlement Class Member, or made available on the Settlement Website, to the Settlement Administrator to recover payment. ECF No. 376-3 at 17–18 (Settlement Agreement, § 3.2(e)(ii)). The Settlement Agreement also provides that, upon submission of a valid Claim Form, the Settlement Class Members may receive $20 per unit of VSL#3 that they purchased, subject to pro rata adjustments based on the volume of the claims received. ECF No. 376-3 at 14–15 (Settlement Agreement, § 2.4), 16—20 (Settlement Agreement, § 3.2) and 20–21 (Settlement Agreement, § 3.3). Pursuant to the terms of the Settlement Agreement, the Settlement Administrator will review all Claims to determine their validity and decide whether to grant, or deny the Claim. Id. at 18 (Settlement Agreement, § 3.2(e)(iii)). If the total value of the approved Claims exceeds the funds available, the payments will be reduced on a pro rata basis. Id. at 19 (Settlement Agreement, § 3.2 (e)(ix)). Similarly, if the total value of the approved Claims is less than the funds available, the payments will be increased on a pro rata basis. Id. (Settlement Agreement, § 3.2 (e)(ix)). The Settlement Agreement also provides that the Settlement Administrator will pay all Claims within 30 days of notifying Settlement Class Counsel and the Defendants of the amount of the Net Settlement Fund and Claims Payment payable, absent any objections. Id. (Settlement Agreement, § 3.2 (e)(x)).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Eisen v. Carlisle & Jacquelin
417 U.S. 156 (Supreme Court, 1974)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Stillmock v. Weis Markets, Inc.
385 F. App'x 267 (Fourth Circuit, 2010)
In Re Jiffy Lube Securities Litigation
927 F.2d 155 (Fourth Circuit, 1991)
Williams v. Henderson
129 F. App'x 806 (Fourth Circuit, 2005)
Cuthie v. FLEET RESERVE ASS'N
743 F. Supp. 2d 486 (D. Maryland, 2010)
Teresa Speaks v. U. S. Tobacco Cooperative Inc.
917 F.3d 276 (Fourth Circuit, 2019)
Kenneth Bell v. Durant Brockett
922 F.3d 502 (Fourth Circuit, 2019)
Pia McAdams v. Nationstar Mortgage
26 F.4th 149 (Fourth Circuit, 2022)
Robinson v. Fountainhead Title Group Corp.
252 F.R.D. 275 (D. Maryland, 2008)
Peoples v. Wendover Funding, Inc.
179 F.R.D. 492 (D. Maryland, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
David Starr et al. v. VSL Pharmaceuticals, Inc. et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/david-starr-et-al-v-vsl-pharmaceuticals-inc-et-al-mdd-2026.